tretinoin and Staphylococcal-Infections

tretinoin has been researched along with Staphylococcal-Infections* in 9 studies

Trials

1 trial(s) available for tretinoin and Staphylococcal-Infections

ArticleYear
Staphylococcus aureus infection as a complication of isotretinoin therapy.
    Archives of dermatology, 1987, Volume: 123, Issue:5

    Eighteen patients developed Staphylococcus aureus infection during or shortly after a five-month course of therapy with isotretinoin. Staphylococcus aureus was recovered both from lesions and from the anterior nares. In a prospective study, 4% of control patients treated with isotretinoin alone developed S aureus infection, while none who applied topical antibiotic to the anterior nares developed infection. Control patients had a 64% prevalence of anterior nares colonization with S aureus, compared with 18% in the topical antibiotic group.

    Topics: Administration, Topical; Anti-Bacterial Agents; Dermatitis; Humans; Isotretinoin; Ointments; Staphylococcal Infections; Staphylococcus aureus; Tretinoin

1987

Other Studies

8 other study(ies) available for tretinoin and Staphylococcal-Infections

ArticleYear
Retinoids Enhance the Expression of Cathelicidin Antimicrobial Peptide during Reactive Dermal Adipogenesis.
    Journal of immunology (Baltimore, Md. : 1950), 2019, 09-15, Volume: 203, Issue:6

    A subset of dermal fibroblasts undergo rapid differentiation into adipocytes in response to infection and acutely produce the cathelicidin antimicrobial peptide gene

    Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Antimicrobial Cationic Peptides; Cathelicidins; Cell Differentiation; Cell Line; Dermis; Fibroblasts; Keratinocytes; Mice; Retinoids; Skin; Staphylococcal Infections; Staphylococcus aureus; Tretinoin

2019
Persistent methicillin-resistant Staphylococcus aureus bacteremia owing to placental abscess.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018, Volume: 24, Issue:12

    Staphylococcus aureus as a pathogen in human gestational membranes, a rather rare phenomenon, has recently been the focus of several researches. S. aureus forms biofilms on these membranes and potentially causes chorioamnionitis in pregnant women. We report a case of persistent methicillin-resistant S. aureus (MRSA) bacteremia owing to placental infection, causing chorioamnionitis and preterm birth. A 29-year-old Japanese woman at the 27th gestational week was diagnosed with acute promyelocytic leukemia and underwent all-trans retinoic acid therapy. Soon after hospitalization, the patient presented with persistent MRSA bacteremia of unknown origin. Despite various antimicrobial therapies, she experienced 12 MRSA bacteremia episodes over 6 weeks. However, after child birth, MRSA bacteremia disappeared without any complications. A pathologic examination of her placenta revealed placenta abscess, resulting in a diagnosis of MRSA-associated chorioamnionitis. Molecular analysis proved that a single MRSA strain (SCCmec Type IVa), which tested negative for Panton-Valentine leukocidin and toxic shock syndrome toxin-1, caused the obstinate infection. We should be aware that persistent MRSA bacteremia in pregnant women can originate from placental abscess.

    Topics: Abdominal Abscess; Adult; Bacteremia; Bacterial Toxins; Chorioamnionitis; Exotoxins; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Pancytopenia; Placenta; Pregnancy; Staphylococcal Infections; Tretinoin

2018
Lung injury caused by all-trans-retinoic acid in the treatment of acute promyelocytic leukemia.
    Archivos de bronconeumologia, 2016, Volume: 52, Issue:8

    Topics: Acute Lung Injury; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Catheter-Related Infections; Dexamethasone; Dyspnea; Fever; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Staphylococcal Infections; Tretinoin

2016
Non-ablative fractional laser assists cutaneous delivery of small- and macro-molecules with minimal bacterial infection risk.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Sep-20, Volume: 92

    Use of the ablative laser has been approved to enhance topical drug penetration. Investigation into the usefulness of the non-ablative laser for assisting drug delivery is very limited. In this study, we explored the safety and efficacy of the non-ablative fractional erbium:glass (Er:glass) laser as an enhancement approach to promote drug permeation. Both pig and nude mouse skins were employed as transport barriers. We histologically examined the skin structure after laser exposure. The permeants of 5-aminolevulinic acid (ALA), imiquimod, tretinoin, peptide, dextrans and quantum dots (QD) were used to evaluate in vitro and in vivo skin passage. The fractional laser selectively created an array of photothermal dots deep into the dermis with the preservation of the stratum corneum and epidermis. The barrier function of the skin could be recovered 8-60h post-irradiation depending on the laser spot densities. The application of the laser caused no local infection of Staphylococcus aureus and Pseudomonas aeruginosa. Compared to intact skin, ALA flux was enhanced up to 1200-fold after laser exposure. The penetration enhancement level by the laser was decreased following the increase of permeant lipophilicity. The skin accumulation of tretinoin, an extremely lipophilic drug, showed only a 2-fold elevation by laser irradiation. The laser promoted peptide penetration 10-fold compared to the control skin. Skin delivery of dextrans with a molecular weight (MW) of at least 40kDa could be achieved with the Er:glass laser. QD with a diameter of 20nm penetrated into the skin with the assistance of the non-ablative laser. The confocal microscopic images indicated the perpendicular and lateral diffusions of dextrans and nanoparticles via laser-created microscopic thermal zones. Controlled Er:glass laser irradiation offers a valid enhancement strategy to topically administer the permeants with a wide MW and lipophilicity range.

    Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Animals; Dextrans; Drug Delivery Systems; Fluorescein; Fluorescein-5-isothiocyanate; Imiquimod; Lasers, Solid-State; Mice, Inbred BALB C; Mice, Nude; Peptides; Pseudomonas aeruginosa; Pseudomonas Infections; Quantum Dots; Skin; Skin Absorption; Staphylococcal Infections; Staphylococcus aureus; Swine; Tretinoin

2016
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen.
    Leukemia, 2003, Volume: 17, Issue:5

    Infections represent a frequent complication of chemotherapy used for acute myeloid leukaemia (AML) and are associated with important toxicity frequently leading to treatment discontinuation. Acute promyelocytic leukaemia (APL) is a unique AML subset requiring tailored therapy including all-trans retinoic acid and anthracycline-based chemotherapy. We analysed in this study the incidence and type of infections complicating the clinical course of 89 consecutive APL patients receiving the AIDA protocol at a single institution. A total of 179 febrile episodes were registered during induction and consolidation, 52% of which were of unknown origin. Infections were clinically and microbiologically documented in 10.6 and 37.4% of cases, respectively. Coagulase-negative staphylococci represented the major cause of septicaemia (28%) and were more frequently isolated during induction, whereas viridans group streptococci, the second pathogen most frequently isolated from blood (27%), represented the principal pathogen detected during consolidation and were significantly associated with mucositis. Gram-negative bacteria accounted for 33.3% of all blood isolates. Fungal infections were only occasionally observed. Bloodstream infections in APL patients were compared with those documented in 271 consecutive patients affected by other subtypes of AML. The incidence of total septicaemia episodes, of staphylococcal bacteraemias and of fungaemias was significantly higher in patients with other AMLs. Empirical antibiotic therapy with ceftriaxone plus amikacin was effective in 73% of APL cases, most of the remaining cases being successfully managed by the addition of teicoplanin. One single death apparently related to infectious complication was recorded. Overall, infections led to antileukaemic treatment withdrawal in six patients, five of whom currently remain in haematologic remission for 13-106 months. These results indicate that a particular pattern of infections is observed in APL patients receiving ATRA plus anthracycline-based chemotherapy and that these appear to be effectively counteracted by standard management.

    Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Ceftazidime; Child; Child, Preschool; Drug Therapy, Combination; Female; Fever; Gram-Positive Bacteria; Humans; Idarubicin; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Staphylococcal Infections; Streptococcal Infections; Tretinoin

2003
Hyperimmunoglobulin E syndrome: treatment with isotretinoin.
    The British journal of dermatology, 1988, Volume: 119, Issue:1

    A patient with hyperimmunoglobulin E syndrome is described. Recurrent cutaneous staphylococcal abscesses were a prominent feature and had been resistant to treatment with antibiotics and surgical drainage. Following a 4-month course of treatment with isotretinoin, he developed no further abscesses over a 6-month follow-up period. Detailed immunological investigations were undertaken before and after treatment and no change was found to account for his improvement. We consider that the beneficial effects of isotretinoin in this situation are likely to be due to a reduction in sebaceous gland size and activity, rather than to any effect on the underlying disorder.

    Topics: Abscess; Adolescent; Humans; Hypergammaglobulinemia; Immunoglobulin E; Isotretinoin; Male; Skin Diseases, Infectious; Staphylococcal Infections; Tretinoin

1988
Isotretinoin and Staphylococcus aureus infection. A possible association.
    Archives of dermatology, 1986, Volume: 122, Issue:7

    The use of isotretinoin (13-cis-retinoic acid) in the treatment of numerous dermatologic disorders, as well as the side effects encountered with use of the drug, have increased remarkably since its release. We encountered a case of Staphylococcus aureus endocarditis in a patient with chronic stable aortic insufficiency undergoing therapy with isotretinoin for extensive actinic keratoses. Although significant dysfunction of the immune system has not been demonstrated with isotretinoin, nasal colonization with S aureus has been shown to occur. Changes in skin fragility caused by the drug may provide a portal of entry for the organism. Physicians should be alert for this potential complication in patients with an underlying cardiac valvular lesion; antibiotic prophylaxis may be indicated in this group during isotretinoin therapy.

    Topics: Aortic Valve Insufficiency; Endocarditis, Bacterial; Humans; Isomerism; Isotretinoin; Keratosis; Male; Middle Aged; Risk; Skin; Staphylococcal Infections; Staphylococcus aureus; Tretinoin

1986
Blepharoconjunctivitis: a side effect of 13-cis-retinoic acid therapy for dermatologic diseases.
    Ophthalmology, 1979, Volume: 86, Issue:5

    Blepharoconjunctivitis developed as a side-effect of treatment of patients with basal cell carcinomas, keratinizing dermatoses, and cystic acne with oral 13-cis-retinoic acid. Forty-two of the 97 dermatologic patients had signs and symptoms of blepharoconjunctivitis that were dose related and abated one week after discontinuation of the medication. About half of the patients had a history of similar symptoms prior to treatment. Staphylococcus aureus was present in eye cultures of 73% to 79% of the patients, whether symptomatic or not. Patients whose clinical appearance was that of staphylococcal blepharoconjunctivitis and whose cultures grew S aureus were successfully treated with topical erythromycin ointment to the lids even while being treated with the 13-cis-retinoic acid.

    Topics: Acne Vulgaris; Blepharitis; Carcinoma, Basal Cell; Conjunctivitis; Erythromycin; Eyelid Diseases; Humans; Keratosis; Skin Diseases; Skin Neoplasms; Staphylococcal Infections; Tretinoin

1979